weight regain and cardiometabolic effects after withdrawal of semaglutide Clinical Management Consequences Discontinuation of GLP‐1 Receptor Agonists - Shah - 2026 - Diabetes, Obesity and Metabolism Semaglutide in Cardiometabolic Diseases: SELECTing

Researchers at Case Western Reserve University found that people with type 2 diabetes who took semaglutide (the active ingredient in Ozempic and Wegovy) had a significantly lower risk of developing dementia

Encourage people living with obesity to engage with weight management programmes

back of your upper arm

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are newer medications used to treat type 2 diabetes mellitus (T2DM) and obesity

Taking semaglutide (Ozempic) and tirzepatide together is not clinically advised due to overlapping mechanisms and safety concerns

Understand how GLP-1 medications affect digestion, causing bloating and constipation, and learn strategies to manage symptoms while supporting your gut health.